UnitedHealth Group: «slow and steady wins the race»
Show Me the Money! 16 July, 2020, by Vladimir Rojankovski, Chief Analyst, Grand Capital
UnitedHealth Group reported a solid quarter in which strength in premiums offset weakness routinely associated by many with COVID. The company reported $62.14 billion in revenue, a slight miss – not by a wide margin, and we tend to play it down when the company is growing its product pipeline. Q2 revenue is up 2.5% from the same period last year and drove a solid increase in net income. EPS, both adjusted and GAAP, beat consensus by double-digits to post near-100% increases from the previous year. The caveat is additional expenditures will reach the company in the 3rd quarter but not enough to impact the full-year guidance.
Technically, UnitedHealth is in ascending trend with 320 dollars as interim price target – seemingly not that much of an upside, but they call it «slow and steady wins the race».
UnitedHealth Group reported a solid quarter in which strength in premiums offset weakness routinely associated by many with COVID. The company reported $62.14 billion in revenue, a slight miss – not by a wide margin, and we tend to play it down when the company is growing its product pipeline. Q2 revenue is up 2.5% from the same period last year and drove a solid increase in net income. EPS, both adjusted and GAAP, beat consensus by double-digits to post near-100% increases from the previous year. The caveat is additional expenditures will reach the company in the 3rd quarter but not enough to impact the full-year guidance.
Technically, UnitedHealth is in ascending trend with 320 dollars as interim price target – seemingly not that much of an upside, but they call it «slow and steady wins the race».